Photo from wikipedia
Despite most controlled trials have shown no measurable benefit of COVID‐19 convalescent plasma (CCP) in patients with COVID‐19, some studies suggest that early administration of CCP with high‐titer anti‐SARS‐CoV‐2 can… Click to show full abstract
Despite most controlled trials have shown no measurable benefit of COVID‐19 convalescent plasma (CCP) in patients with COVID‐19, some studies suggest that early administration of CCP with high‐titer anti‐SARS‐CoV‐2 can be beneficial in selected patients. We investigated the efficacy of early administration of high‐titer CCP to patients with COVID‐19 who required hospitalization,
Keywords:
high titer;
efficacy early;
patients covid;
convalescent plasma;
sars cov
Journal Title: Transfusion
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!